Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study

(2015) L Dickinson et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics

(2015) A Olagunju et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study

(2015)   LANCET INFECTIOUS DISEASES

Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols

(2015) David S. Lehmann et al.   Pharmacogenetics and Genomics

Pharmacokinetics of Efavirenz and Treatment of HIV-1 Among Pregnant Women With and Without Tuberculosis Coinfection

(2014) Kelly E. Dooley et al.   JOURNAL OF INFECTIOUS DISEASES

Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial

(2014)   LANCET

CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults

(2014) Adeniyi Olagunju et al.   Pharmacogenetics and Genomics

CYP2B6 516G>T (rs3745274) and Smoking Status Are Associated With Efavirenz Plasma Concentration in a Serbian Cohort of HIV Patients

(2014) Adeniyi Olagunju et al.   THERAPEUTIC DRUG MONITORING

Relationship Between Weight, Efavirenz Exposure, and Virologic Suppression in HIV-Infected Patients on Rifampin-Based Tuberculosis Treatment in the AIDS Clinical Trials Group A5221 STRIDE Study

(2013) Anne F. Luetkemeyer et al.   CLINICAL INFECTIOUS DISEASES

Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in tororo, uganda

(2013) Imke H. Bartelink et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants

(2012) Emily R. Holzinger et al.   Pharmacogenetics and Genomics

Determinants of Sustained Viral Suppression in HIV-Infected Patients with Self-Reported Poor Adherence to Antiretroviral Therapy

(2012) Tracy R. Glass et al.   PLoS One

Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis

(2011) E Ngaimisi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Efavirenz Pharmacokinetics During the Third Trimester of Pregnancy and Postpartum

(2011) Tim R. Cressey et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens

(2011) C. Wyen et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Population Pharmacokinetic Modeling of the Association between 63396C->T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance

(2010) A. Schipani et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Association of a Single‐Nucleotide Polymorphism in the Pregnane X Receptor (PXR63396C→T) with Reduced Concentrations of Unboosted Atazanavir

(2008) Marco Siccardi et al.   CLINICAL INFECTIOUS DISEASES